May 9, 2023

 

VIA EDGAR SUBMISSION

 

U.S. Securities and Exchange Commission

Division of Corporation Finance, Office of Life Sciences

100 F Street, NE

Washington, DC 20549

 

Attention:

Daniel Crawford

 

Re:

Kala Pharmaceuticals, Inc.

Registration Statement on Form S-3

Filed March 3, 2023
File No. 333-270263
Request for Acceleration

 
Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kala Pharmaceuticals, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-270263), so that it may become effective at 4:00 p.m., Eastern Time, on May 11, 2023, or as soon as practicable thereafter.

 

	Very truly yours, KALA PHARMACEUTICALS, INC.
	By:	/s/ Eric L. Trachtenberg
	Name: Eric L. Trachtenberg
	Title: General Counsel, Chief Compliance Officer and Corporate Secretary